Cargando…

The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome

BACKGROUND: The monocyte to high-density lipoprotein cholesterol ratio (MHR) has been demonstrated as a new marker of inflammation. However, at present, the prognostic value of MHR in type 2 diabetes mellitus (T2DM) accompanied with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chen, Fan, Hualin, Liu, Yuanhui, Zeng, Lihuan, Chen, Pengyuan, Duan, Chongyang, Liang, Huasheng, He, Pengcheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640916/
https://www.ncbi.nlm.nih.gov/pubmed/34926671
http://dx.doi.org/10.21037/atm-21-4876
_version_ 1784609409190592512
author Li, Chen
Fan, Hualin
Liu, Yuanhui
Zeng, Lihuan
Chen, Pengyuan
Duan, Chongyang
Liang, Huasheng
He, Pengcheng
author_facet Li, Chen
Fan, Hualin
Liu, Yuanhui
Zeng, Lihuan
Chen, Pengyuan
Duan, Chongyang
Liang, Huasheng
He, Pengcheng
author_sort Li, Chen
collection PubMed
description BACKGROUND: The monocyte to high-density lipoprotein cholesterol ratio (MHR) has been demonstrated as a new marker of inflammation. However, at present, the prognostic value of MHR in type 2 diabetes mellitus (T2DM) accompanied with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) is unclear. METHODS: T2DM patients with NSTE-ACS undergoing PCI were consecutively enrolled from January 1, 2010 to December 31, 2014 and divided according to MHR value tertiles. Baseline, procedural, and follow-up data were collected. The primary outcomes were in-hospital major adverse clinical events (MACE). The prespecified secondary outcomes included any bleeding [as indicated by Bleeding Academic Research Consortium definition (BARC) grades 1–5] and death during follow-up. RESULTS: Of the 1,405 enrolled patients, the rates of in-hospital MACE (0.2%, 0.2%, and 1.3%, P=0.043) and bleeding (12.4%, 12.2%, and 17.1%, P=0.048) increased significantly in high MHR tertiles. After 1 year of follow-up, the rates of bleeding (15.0%, 14.5%, and 22.2%, P=0.002) and all-cause death (1.5%, 1.7%, and 4.3%, P=0.010) were higher in higher MHR tertiles. Our results also suggested that MHR was an independent predictor of in-hospital MACE [adjusted odds ratio =8.36; 95% confidence interval (CI): 1.57–44.47; P=0.013] and long-term bleeding (adjusted hazard ratio =1.21; 95% CI: 1.07–1.37; P=0.002). Receiver-operating characteristic curve analysis indicated that MHR >0.022 had a sensitivity of 75.0% and specificity of 72.7% for predicting in-hospital MACE [area under the curve (AUC) =0.722; 95% CI: 0.51–0.933; P=0.040]. Furthermore, Kaplan-Meier curves showed that a higher risk of all-cause death in long-term follow-up was prevalent in patients with high MHR (P=0.033). CONCLUSIONS: The increased level of MHR was related to in-hospital MACE and long-term bleeding events in T2DM patients with NSTE-ACS undergoing PCI.
format Online
Article
Text
id pubmed-8640916
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-86409162021-12-16 The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome Li, Chen Fan, Hualin Liu, Yuanhui Zeng, Lihuan Chen, Pengyuan Duan, Chongyang Liang, Huasheng He, Pengcheng Ann Transl Med Original Article BACKGROUND: The monocyte to high-density lipoprotein cholesterol ratio (MHR) has been demonstrated as a new marker of inflammation. However, at present, the prognostic value of MHR in type 2 diabetes mellitus (T2DM) accompanied with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) is unclear. METHODS: T2DM patients with NSTE-ACS undergoing PCI were consecutively enrolled from January 1, 2010 to December 31, 2014 and divided according to MHR value tertiles. Baseline, procedural, and follow-up data were collected. The primary outcomes were in-hospital major adverse clinical events (MACE). The prespecified secondary outcomes included any bleeding [as indicated by Bleeding Academic Research Consortium definition (BARC) grades 1–5] and death during follow-up. RESULTS: Of the 1,405 enrolled patients, the rates of in-hospital MACE (0.2%, 0.2%, and 1.3%, P=0.043) and bleeding (12.4%, 12.2%, and 17.1%, P=0.048) increased significantly in high MHR tertiles. After 1 year of follow-up, the rates of bleeding (15.0%, 14.5%, and 22.2%, P=0.002) and all-cause death (1.5%, 1.7%, and 4.3%, P=0.010) were higher in higher MHR tertiles. Our results also suggested that MHR was an independent predictor of in-hospital MACE [adjusted odds ratio =8.36; 95% confidence interval (CI): 1.57–44.47; P=0.013] and long-term bleeding (adjusted hazard ratio =1.21; 95% CI: 1.07–1.37; P=0.002). Receiver-operating characteristic curve analysis indicated that MHR >0.022 had a sensitivity of 75.0% and specificity of 72.7% for predicting in-hospital MACE [area under the curve (AUC) =0.722; 95% CI: 0.51–0.933; P=0.040]. Furthermore, Kaplan-Meier curves showed that a higher risk of all-cause death in long-term follow-up was prevalent in patients with high MHR (P=0.033). CONCLUSIONS: The increased level of MHR was related to in-hospital MACE and long-term bleeding events in T2DM patients with NSTE-ACS undergoing PCI. AME Publishing Company 2021-11 /pmc/articles/PMC8640916/ /pubmed/34926671 http://dx.doi.org/10.21037/atm-21-4876 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Li, Chen
Fan, Hualin
Liu, Yuanhui
Zeng, Lihuan
Chen, Pengyuan
Duan, Chongyang
Liang, Huasheng
He, Pengcheng
The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome
title The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome
title_full The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome
title_fullStr The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome
title_full_unstemmed The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome
title_short The monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-ST-segment elevation acute coronary syndrome
title_sort monocyte to high-density lipoprotein cholesterol ratio and outcomes in type 2 diabetes mellitus patients with non-st-segment elevation acute coronary syndrome
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8640916/
https://www.ncbi.nlm.nih.gov/pubmed/34926671
http://dx.doi.org/10.21037/atm-21-4876
work_keys_str_mv AT lichen themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT fanhualin themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT liuyuanhui themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT zenglihuan themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT chenpengyuan themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT duanchongyang themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT lianghuasheng themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT hepengcheng themonocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT lichen monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT fanhualin monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT liuyuanhui monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT zenglihuan monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT chenpengyuan monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT duanchongyang monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT lianghuasheng monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome
AT hepengcheng monocytetohighdensitylipoproteincholesterolratioandoutcomesintype2diabetesmellituspatientswithnonstsegmentelevationacutecoronarysyndrome